# Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

> **NCT06609356** · EARLY_PHASE1 · RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 27 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus
- Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)
- MODY2 Diabetes
- Healthy Volunteer

## Interventions

- **PROCEDURE:** Study Visit 1
- **DRUG:** Placebo
- **PROCEDURE:** Study Visit 2
- **DRUG:** Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor

## Key facts

- **NCT ID:** NCT06609356
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-03
- **Primary completion:** 2027-07
- **Final completion:** 2027-12
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06609356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06609356, "Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06609356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*